National MPS Society Collaborates to Fund MPS III Gene Therapy
Abeona Therapeutics raises $3.6M to develop therapies for children suffering from MPS III. Gene therapy clinical trials for MPS IIIA and MPS IIIB are anticipated to begin in early to mid-2015.
Give to the 2014 Annual Fund: Chair Lynn Hopkins
Meet Lynn Hopkins, our Chair for the 2014 Annual Fund. Lynn and the National MPS Society hope that your family will make a difference by giving to the 2014 Annual Fund and supporting our mission to keep the Society strong.
28th Annual Family Conference – Disney
The Family Conference in Disney is from December 18-20. Click here for the link to register! Registration deadline – November 26, 2014.
Have you considered hosting a walk/run?
Have you been thinking about having a Walk/Run in 2015? Hosting an event is a great way to support the National MPS Society. Find out how!
Mucopolysaccharidoses (MPS) and related diseases are genetic lysosomal storage diseases (LSD) caused by the body's inability to produce specific enzymes. Normally, the body uses enzymes to break down and recycle materials in cells. In individuals with MPS and related diseases, the missing or insufficient enzyme prevents the proper recycling process, resulting in the storage of materials in virtually every cell of the body.